PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming
Science Advances · 26.06.2026 · 12 (26)
DOI: 10.1126/sciadv.aed8866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 26.06.2026. Verfasst von Ruiyang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China. Hauptthemen laut MEDLINE: Sp1 Transcription Factor, Liver Neoplasms, Carcinoma, Hepatocellular, Lipid Metabolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Guangdong Hong Kong Macao University Joint Laboratory of Interventional Medicine Foundation of Guangdong Province.
Abstract (Originalsprache)
Metabolic reprogramming is a hallmark of cancer, yet the critical drivers and mechanisms in hepatocellular carcinoma (HCC) remain incompletely understood. Through a metabolism-focused CRISPR screen, we identified phosphomevalonate kinase (PMVK), a mevalonate pathway enzyme, as a key regulator of HCC stemness and progression. PMVK directly phosphorylates the transcription factor SP1 at Thr 355 , which enhances SP1’s DNA binding affinity and promotes its interaction with the master lipid regulator SREBP1/2, driving a transcriptional program essential for de novo cholesterol and fatty acid synthesis. Clinically, PMVK levels are positively correlated with phospho-SP1 (Thr 355 ) levels and predicate poor prognosis in patients with HCC. Functionally, we demonstrate that genetic or pharmacologic inhibition of the PMVK-SP1 axis, including using the SP1 inhibitor mithramycin A (MTA), significantly suppresses HCC tumorigenesis. In conclusion, our findings uncover the PMVK-SP1 axis as a central driver of lipid metabolic reprogramming and hepatocarcinogenesis, highlighting it as a compelling therapeutic target in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
- Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
- Guangdong-Hong Kong-Macao University Joint of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
- Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Kashi Guangdong Institute of Science and Technology, The First People's Hospital of Kashi, Kashi, Xinjiang Uyghur Autonomous Region, China.
- State Key Laboratory of Anti-Infective Drug Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
ORCID-Profile: Ruiyang Liu, Zhiju Zhao, Fei Xiao
Förderung
- National Natural Science Foundation of China
- Guangdong Hong Kong Macao University Joint Laboratory of Interventional Medicine Foundation of Guangdong Province
Zitieren
APA
Liu, R., Huang, C., Xu, Z., Xu, F., Wen, X., Zhao, Z., & Xiao, F. (2026). PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming. Science Advances, 12(26). https://doi.org/10.1126/sciadv.aed8866
Vancouver
Liu R, Huang C, Xu Z, Xu F, Wen X, Zhao Z, et al. PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming. Science Advances. 2026;12(26). doi:10.1126/sciadv.aed8866
BibTeX
@article{Liu2026,
author = {Liu, Ruiyang and Huang, Caini and Xu, Zhijie and Xu, Fuyuan and Wen, Xinyi and Zhao, Zhiju and Xiao, Fei},
title = {PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {26},
doi = {10.1126/sciadv.aed8866}
}
EUVIMED